These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 10517497

  • 1. Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard: amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery.
    Poloni A, Leoni P, Curzi L, Cantori I, Mancini S, Montanari M, Masia MC, Olivieri A.
    Exp Hematol; 1999 Oct; 27(10):1548-56. PubMed ID: 10517497
    [Abstract] [Full Text] [Related]

  • 2. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
    Douay L, Hu C, Giarratana MC, Bouchet S, Conlon J, Capizzi RL, Gorin NC.
    Blood; 1995 Oct 01; 86(7):2849-55. PubMed ID: 7670119
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.
    Motta MR, Mangianti S, Rizzi S, Ratta M, Campanini E, Fortuna A, Fogli M, Tura S, Lemoli RM.
    Exp Hematol; 1997 Nov 01; 25(12):1261-9. PubMed ID: 9357970
    [Abstract] [Full Text] [Related]

  • 4. Use of amifostine in bone marrow purging.
    Cagnoni PJ, Jones RB, Bearman SI, Ross M, Hami L, Franklin WA, Capizzi R, Schein PS, Shpall EJ.
    Semin Oncol; 1996 Aug 01; 23(4 Suppl 8):44-8. PubMed ID: 8783666
    [Abstract] [Full Text] [Related]

  • 5. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants.
    Douay L, Hu C, Giarratana MC, Gorin NC.
    Semin Oncol; 1994 Oct 01; 21(5 Suppl 11):16-20. PubMed ID: 7973773
    [Abstract] [Full Text] [Related]

  • 6. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
    Balzarotti M, Grisanti S, Granzow K, Saladini A, Sala A, Nozza A, Molteni A, Passamonti F, Carlo-Stella C, Santoro A, Siena S.
    Semin Oncol; 1999 Apr 01; 26(2 Suppl 7):66-71. PubMed ID: 10348263
    [Abstract] [Full Text] [Related]

  • 7. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
    Stilz R, Grünebach F, Bader P, Vogel W, Kanz L, Brugger W, Scheding S.
    J Hematother Stem Cell Res; 2001 Dec 01; 10(6):777-85. PubMed ID: 11798504
    [Abstract] [Full Text] [Related]

  • 8. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors.
    List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL.
    Leukemia; 1998 Oct 01; 12(10):1596-602. PubMed ID: 9766505
    [Abstract] [Full Text] [Related]

  • 9. Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects.
    Douay L, Hu C, Giarratana MC, Gorin NC.
    Eur J Cancer; 1995 Oct 01; 31A Suppl 1():S14-6. PubMed ID: 7577094
    [Abstract] [Full Text] [Related]

  • 10. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
    Bone Marrow Transplant; 1999 Feb 01; 23(3):235-41. PubMed ID: 10084254
    [Abstract] [Full Text] [Related]

  • 11. Effect of Ethiofos on cytotoxicity of pharmacological purging protocols used for autologous marrow grafts in acute lymphoblastic leukemia.
    Skala JP, Rogers PC, Chan KW, Rodriguez WC.
    Prog Clin Biol Res; 1992 Feb 01; 377():57-62. PubMed ID: 1332075
    [No Abstract] [Full Text] [Related]

  • 12. Increased sensitivity of myeloid leukemia cell lines: potential of lovastatin as bone-marrow-purging agent.
    Scheffold C, Schöttker B, Lefterova P, Csipai M, Glasmacher A, Huhn D, Neubauer A, Schmidt-Wolf IG.
    Acta Haematol; 2000 Feb 01; 104(2-3):72-9. PubMed ID: 11154978
    [Abstract] [Full Text] [Related]

  • 13. TGF-beta 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro.
    Lemoli RM, Strife A, Clarkson BD, Haley JD, Gulati SC.
    Exp Hematol; 1992 Dec 01; 20(11):1252-6. PubMed ID: 1493854
    [Abstract] [Full Text] [Related]

  • 14. Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells.
    Widmer L, Pichert G, Jost LM, Stahel RA.
    Blood; 1996 Oct 15; 88(8):3166-75. PubMed ID: 8874217
    [Abstract] [Full Text] [Related]

  • 15. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
    Fauth F, Martin H, Sonnhoff S, Bialleck H, Wiesneth M, Mihanovic B, Hoelzer D.
    Bone Marrow Transplant; 2000 Apr 15; 25(8):831-6. PubMed ID: 10808203
    [Abstract] [Full Text] [Related]

  • 16. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG, Joshi SS, Chan WC, Iversen PL, Jackson JD, Kessinger A, Pirruccello SJ, Sanger WG, Sharp JG, Verbik DJ.
    Leuk Lymphoma; 1995 Dec 15; 20(1-2):67-76. PubMed ID: 8750625
    [Abstract] [Full Text] [Related]

  • 17. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity.
    List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL.
    Semin Oncol; 1996 Aug 15; 23(4 Suppl 8):58-63. PubMed ID: 8783669
    [Abstract] [Full Text] [Related]

  • 18. Differences in heat sensitivity between normal and acute myeloid leukemic stem cells: feasibility of hyperthermic purging of leukemic cells from autologous stem cell grafts.
    Wierenga PK, Setroikromo R, Kamps G, Kampinga HH, Vellenga E.
    Exp Hematol; 2003 May 15; 31(5):421-7. PubMed ID: 12763141
    [Abstract] [Full Text] [Related]

  • 19. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C, Mangoni L, Almici C, Garau D, Craviotto L, Piovani G, Caramatti C, Rizzoli V.
    Exp Hematol; 1992 Mar 15; 20(3):328-33. PubMed ID: 1568448
    [Abstract] [Full Text] [Related]

  • 20. Potentiation of the antitumor effect of Merocyanine 540-mediated photodynamic therapy by amifostine and amphotericin B.
    Tsujino I, Miyagi K, Sampson RW, Sieber F.
    Photochem Photobiol; 2006 Mar 15; 82(2):458-65. PubMed ID: 16613499
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.